Theresa Heggie, a former chief executive of Freeline Therapeutics, has joined ProQR Therapeutics NV as chief commercial officer. ProQR is developing RNA therapies for genetic eye diseases. She joins ahead of the release next year of results from a pivotal trial of the company’s lead product for Leber congenital amaurosis, a rare eye disorder. Ms Heggie has held positions at Alnylam Pharmaceuticals Inc and at Shire, now owned by Takeda Pharmaceutical Co Ltd. She received a bachelor of science degree from Cornell University in the US.
ProQR announced the appointment on 4 October 2021.
Copyright 2021 Evernow Publishing Ltd